California State Teachers Retirement System Sells 11,046 Shares of Elevance Health, Inc. $ELV

California State Teachers Retirement System lowered its holdings in Elevance Health, Inc. (NYSE:ELV) by 3.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 330,807 shares of the company’s stock after selling 11,046 shares during the quarter. California State Teachers Retirement System’s holdings in Elevance Health were worth $96,844,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ELV. WealthCollab LLC boosted its position in shares of Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after acquiring an additional 27 shares during the period. Signet Financial Management LLC increased its position in Elevance Health by 3.5% during the first quarter. Signet Financial Management LLC now owns 837 shares of the company’s stock worth $245,000 after acquiring an additional 28 shares during the period. Fulton Breakefield Broenniman LLC raised its stake in Elevance Health by 3.6% during the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock valued at $289,000 after purchasing an additional 29 shares during the last quarter. Perigon Wealth Management LLC raised its stake in Elevance Health by 2.2% during the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock valued at $481,000 after purchasing an additional 29 shares during the last quarter. Finally, Savvy Advisors Inc. boosted its holdings in Elevance Health by 3.2% in the 4th quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock valued at $343,000 after purchasing an additional 30 shares during the period. 89.24% of the stock is owned by institutional investors.

Insider Transactions at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director owned 10,734 shares in the company, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.34% of the company’s stock.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised multiple earnings estimates. The firm increased its FY2026 EPS forecast to $27.06 from $26.79, FY2027 to $28.83 from $28.51, and FY2028 to $32.49 from $31.77. It also raised estimates for Q2 2027, Q4 2027, Q1 2028 and Q2 2028, indicating improving expectations for Elevance Health’s longer-term profitability.
• Positive Sentiment: Insider buying provided a vote of confidence. A report highlighted purchases of Elevance Health shares by the company’s CEO and chairman, a potentially supportive signal because insider buying can suggest management views the stock as undervalued. Elevance Health Pick of the Week at Smart Insider Following CEO, Chairman Share Purchases
• Neutral Sentiment: Peer comparison offers limited direct impact. A head-to-head survey compared Elevance Health with Aeon Global Health, but the article does not indicate a material change to ELV’s earnings outlook or valuation. Head to Head Survey: Elevance Health and Aeon Global Health
• Negative Sentiment: Analyst commentary remains cautious. A Seeking Alpha analysis said Elevance Health has upside potential but is “not yet a buy,” which may limit buying interest. Investors may also be focused on near-term earnings pressure: the latest quarterly EPS of $7.45 exceeded estimates but declined from $8.84 in the prior-year period. Elevance Health Has Upside, But Not Yet A Buy

Elevance Health Trading Down 2.5%

Shares of ELV stock opened at $376.21 on Thursday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.52. The firm has a fifty day moving average of $397.65 and a 200-day moving average of $356.66. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $436.24. The stock has a market cap of $81.59 billion, a price-to-earnings ratio of 16.72, a P/E/G ratio of 2.22 and a beta of 0.67.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.21 by $1.24. The firm had revenue of $49.83 billion during the quarter, compared to analyst estimates of $48.88 billion. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The company’s quarterly revenue was up .8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $8.84 earnings per share. On average, equities research analysts forecast that Elevance Health, Inc. will post 27.04 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be given a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.8%. The ex-dividend date is Thursday, September 10th. Elevance Health’s dividend payout ratio (DPR) is presently 30.58%.

Analyst Ratings Changes

Several analysts have issued reports on ELV shares. Morgan Stanley raised their price target on shares of Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 4th. Truist Financial increased their target price on shares of Elevance Health from $450.00 to $475.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Weiss Ratings raised Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 18th. Robert W. Baird boosted their price target on Elevance Health from $331.00 to $393.00 and gave the company a “neutral” rating in a research note on Thursday, July 16th. Finally, Wells Fargo & Company cut their price target on Elevance Health from $492.00 to $473.00 and set an “overweight” rating for the company in a report on Thursday, July 16th. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $440.90.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.